STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death

BACKGROUND: In an effort to achieve better cancer therapies, we elucidated the combination cancer therapy of STI571 (an inhibitor of Bcr-Abl and clinically used for chronic myelogenous leukemia) and TNF-related apoptosis-inducing ligand (TRAIL, a developing antitumor agent) in leukemia, colon, and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Duen-Yi, Chao, Yee, Tai, Ming-Hui, Yu, Yang-Hao, Lin, Wan-Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348077/
https://www.ncbi.nlm.nih.gov/pubmed/22462553
http://dx.doi.org/10.1186/1423-0127-19-35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348077/
https://www.ncbi.nlm.nih.gov/pubmed/22462553
http://dx.doi.org/10.1186/1423-0127-19-35

Ejemplares similares